Pardes Biosciences, Inc.
PRDS
$0.02
Change (1 day)
$3.67
Year High
$0.75
Year Low
Categories
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.
P/B ratio for Pardes Biosciences, Inc. (PRDS)
P/B ratio as of 2022: 0.55
According to Pardes Biosciences, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.55. At the end of 2021 the company had a P/B ratio of 0.23.
P/B ratio history for Pardes Biosciences, Inc. from 2020 to 2022
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2022 | 0.55 |
| 2021 | 0.23 |
| 2020 | 0.00 |